Curaleaf Holdings (CURLF) Amortization of Deferred Charges (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Amortization of Deferred Charges of $3.7 million for Q4 2024, down 12.15% year-on-year from $4.2 million in Q1 2024, and up 20.32% on a QoQ basis from $3.1 million in Q3 2024.
Curaleaf Holdings (CURLF) Amortization of Deferred Charges (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Amortization of Deferred Charges for 6 consecutive years, with $3.7 million the latest figure, recorded in Q4 2024.
- Quarterly Amortization of Deferred Charges fell 12.15% year-over-year to $3.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $15.1 million (up 297.68% YoY) and the FY2025 annual result came in at $19.4 million, up 17.39% from the prior year.
- Amortization of Deferred Charges advanced to $3.7 million in Q4 2024 per CURLF's latest filing, from $3.1 million in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for CURLF reached as high as $13.4 million in Q3 2021 and fell as low as -$19.9 million in Q4 2021.
- A 5-year average of $2.8 million and a median of $3.9 million in 2023 frame the typical range for Amortization of Deferred Charges.
- The largest YoY upside for Amortization of Deferred Charges was 4116.16% in 2021 against a maximum downside of 1098.14% in 2021.
- Year by year, Amortization of Deferred Charges stood at $2.0 million in 2020, then tumbled by 1098.14% to -$19.9 million in 2021, then jumped by 103.2% to $636000.0 in 2022, then surged by 561.32% to $4.2 million in 2023, then fell by 12.15% to $3.7 million in 2024.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $3.7 million, $3.1 million, and $4.2 million for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 6.94 Bn | 6.94 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.70 Mn |
| Dec 31, 2024 | 3.70 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Dec 31, 2023 | 4.21 Mn |
| Dec 31, 2023 | 4.21 Mn |
| Sep 30, 2023 | 4.13 Mn |
| Sep 30, 2023 | 4.13 Mn |
| Dec 31, 2022 | 636,000.00 |
| Dec 31, 2022 | 636,000.00 |
| Sep 30, 2022 | -16.61 Mn |
| Sep 30, 2022 | -16.61 Mn |
| Jun 30, 2022 | 13.12 Mn |
| Jun 30, 2022 | 13.12 Mn |
| Mar 31, 2022 | 12.51 Mn |
| Mar 31, 2022 | 12.51 Mn |
| Dec 31, 2021 | -19.85 Mn |
| Dec 31, 2021 | -19.85 Mn |
| Sep 30, 2021 | 13.40 Mn |
| Sep 30, 2021 | 13.40 Mn |